NASDAQ:KALV KalVista Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.84 +0.16 (+1.65%) (As of 06/30/2022 12:00 AM ET) Add Compare Share Today's Range$9.29▼$9.9250-Day Range$8.16▼$13.6152-Week Range$8.00▼$24.80Volume99,939 shsAverage Volume268,694 shsMarket Capitalization$241.50 millionP/E RatioN/ADividend YieldN/APrice Target$47.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Stock Forecast (MarketRank)Overall MarketRank™1.81 out of 5 starsMedical Sector795th out of 1,433 stocksPharmaceutical Preparations Industry385th out of 684 stocksAnalyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.00, KalVista Pharmaceuticals has a forecasted upside of 377.6% from its current price of $9.84.Amount of Analyst CoverageKalVista Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.9 Community Rank Outperform VotesKalVista Pharmaceuticals has received 313 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKalVista Pharmaceuticals has received 115 “underperform” votes. (Add your “underperform” vote.)Community SentimentKalVista Pharmaceuticals has received 73.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about KalVista Pharmaceuticals and other stocks. Vote “Outperform” if you believe KALV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of KalVista Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to decrease in the coming year, from ($3.45) to ($3.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About KalVista Pharmaceuticals (NASDAQ:KALV)KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.Read More KALV Stock News HeadlinesJune 23, 2022 | finance.yahoo.comKalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)June 9, 2022 | americanbankingnews.comAnalysts Set Expectations for KalVista Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:KALV)June 8, 2022 | finance.yahoo.comKalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor ProgramJune 3, 2022 | finance.yahoo.comWill KalVista Pharmaceuticals (NASDAQ:KALV) Spend Its Cash Wisely?June 1, 2022 | finance.yahoo.comKalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare ConferenceMay 28, 2022 | finanznachrichten.deKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Changes to Board of DirectorsMay 17, 2022 | benzinga.comKalVista Pharmaceuticals Announces Non-...May 17, 2022 | finance.yahoo.comKalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900April 11, 2022 | finance.yahoo.comKalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare ConferenceMarch 22, 2022 | finance.yahoo.comKalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental AllergyMarch 11, 2022 | finanznachrichten.deKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Third Fiscal Quarter ResultsMarch 11, 2022 | benzinga.comNeedham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $42March 10, 2022 | benzinga.comKalVista Pharmaceuticals: Q3 Earnings InsightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALV CUSIPN/A CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees70Year FoundedN/ACompany Calendar Last Earnings12/09/2021Today7/01/2022Next Earnings (Estimated)7/12/2022Fiscal Year End4/30/2023Price Target and Rating Average Stock Price Forecast$47.00 High Stock Price Forecast$51.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+377.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.030010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.70% Return on Assets-29.63% Debt Debt-to-Equity RatioN/A Current Ratio22.23 Quick Ratio22.23 Sales & Book Value Annual Sales$12.69 million Price / Sales19.03 Cash FlowN/A Price / Cash FlowN/A Book Value$10.53 per share Price / Book0.93Miscellaneous Outstanding Shares24,543,000Free Float22,972,000Market Cap$241.50 million OptionableNot Optionable Beta1.82 KalVista Pharmaceuticals Frequently Asked Questions Should I buy or sell KalVista Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KalVista Pharmaceuticals stock. View analyst ratings for KalVista Pharmaceuticals or view top-rated stocks. What is KalVista Pharmaceuticals' stock price forecast for 2022? 4 brokerages have issued twelve-month target prices for KalVista Pharmaceuticals' shares. Their KALV stock forecasts range from $42.00 to $51.00. On average, they expect KalVista Pharmaceuticals' stock price to reach $47.00 in the next year. This suggests a possible upside of 377.6% from the stock's current price. View analysts' price targets for KalVista Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has KalVista Pharmaceuticals' stock price performed in 2022? KalVista Pharmaceuticals' stock was trading at $13.23 at the beginning of 2022. Since then, KALV stock has decreased by 25.6% and is now trading at $9.84. View the best growth stocks for 2022 here. When is KalVista Pharmaceuticals' next earnings date? KalVista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, July 12th 2022. View our earnings forecast for KalVista Pharmaceuticals. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its quarterly earnings results on Thursday, December, 9th. The specialty pharmaceutical company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $0.01. View KalVista Pharmaceuticals' earnings history. Who are KalVista Pharmaceuticals' key executives? KalVista Pharmaceuticals' management team includes the following people: Mr. Thomas Andrew Crockett M.B.A., CEO & Director (Age 47, Pay $1.03M)Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 56, Pay $711.85k)Dr. Christopher M. Yea Ph.D., Chief Devel. Officer (Age 58, Pay $697.34k)Dr. Edward P. Feener Ph.D., Chief Scientific Officer (Age 62)Jarrod Aldom, VP of Corp. CommunicationsMs. Rachel Morten, Head of Regulatory Affairs and QADr. Michael D. Smith Pharm.D., Sr. VP of Devel. (Age 43)Dr. Paul K. Audhya M.B.A., M.D., Chief Medical OfficerMr. Stephen Donnelly, Director of Fin. and Company Sec.Mr. John B. McKune, VP of Fin. (Age 46) Who are some of KalVista Pharmaceuticals' key competitors? Some companies that are related to KalVista Pharmaceuticals include Chinook Therapeutics (KDNY), Amneal Pharmaceuticals (AMRX), Amneal Pharmaceuticals (AMRX), MannKind (MNKD), Avid Bioservices (CDMO), I-Mab (IMAB), Aclaris Therapeutics (ACRS), Rocket Pharmaceuticals (RCKT), Veru (VERU), Deciphera Pharmaceuticals (DCPH), uniQure (QURE), SIGA Technologies (SIGA), ADVANZ PHARMA (CXRXF), Morphic (MORF) and Design Therapeutics (DSGN). View all of KALV's competitors. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE). What is KalVista Pharmaceuticals' stock symbol? KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV." How do I buy shares of KalVista Pharmaceuticals? Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is KalVista Pharmaceuticals' stock price today? One share of KALV stock can currently be purchased for approximately $9.84. How much money does KalVista Pharmaceuticals make? KalVista Pharmaceuticals (NASDAQ:KALV) has a market capitalization of $241.50 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-46.24 million in net income (profit) each year or ($3.030010) on an earnings per share basis. How many employees does KalVista Pharmaceuticals have? KalVista Pharmaceuticals employs 70 workers across the globe. How can I contact KalVista Pharmaceuticals? KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The official website for KalVista Pharmaceuticals is www.kalvista.com. The specialty pharmaceutical company can be reached via phone at 857-999-0075, via email at [email protected], or via fax at 866-553-3269. This page (NASDAQ:KALV) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
